key: cord-0905611-ipjfdnwt
authors: Guo, Yingyi; Qu, Jiuxin; Cheng, Lingling; Li, Xiaohe; Liu, Ningjing; Li, Tungngai; Jiang, Ying; Wan, Qiao; Zhuo, Chuyue; Xiao, Shunian; Liu, Baomo; Chen, Yan; Fu, lin; Chen, Zhixu; Ma, Mingcong; zhuo, Chao; Zhong, Nanshan
title: Incidence and Characteristics of Co-infection and Secondary Infection in Patients with COVID-19
date: 2021-01-06
journal: bioRxiv
DOI: 10.1101/2021.01.06.425542
sha: d11dfd18aceb3cc24ed2aaa49dd4ebe4ce9f5200
doc_id: 905611
cord_uid: ipjfdnwt

Objective The etiology and epidemiology of co-infection and secondary infection in COVID-19 patients remain unknown. The study aims to investigate the occurrence and characteristics of co-infection and secondary infection in COVID-19 patients, mainly focusing on Streptococcus pneumoniae co-infections. Methods This study was a prospective, observational cohort study of the inpatients diagnosed with COVID-19 in two designated hospitals in south China enrolled between Jan 11 and Feb 22, 2020. The urine specimen was collected on admission and applied for pneumococcal urinary antigen tests (PUATs). Demographic, clinical and microbiological data of patients were recorded simultaneously. Result A total of 146 patients with a confirm diagnosis of COVID-19 at the median age of 50.0 years (IQR 36.0-61.0) were enrolled, in which, 16 (11.0%) were classified as severe cases and 130 (89.0%) as non-severe cases. Of the enrolled patients, only 3 (2.1%) were considered to present the co-infection, in which 1 was co-infected with S.pneumoniae, 1 with B. Ovatus infection and the other one with Influenza A virus infection. Secondary infection occurred in 16 patients, with S. maltophilia as the most commonly isolated pathogen (43.8%), followed by P. aeruginosa (25.0%), E. aerogenes (25.0%), C. parapsilosis (25.0%) and A. fumigates (18.8%). Conclusion Patients with confirmed COVID-19 were rarely co-infected with Streptococcus pneumoniae or other pathogens, indicating that the application of antibiotics against CAP on admission may not be necessary in the treatment of COVID-19 cases.

Based on the few published papers, the lack of evidences of occurrence of co-infecting with 69 streptococcus pneumoniae and other pathogens in COVID-19 patients may cause the concern 70 for the rational use of antibiotics in the therapeutic process.

[4] 71 This study mainly aims to investigate the incidence and characteristics of streptococcus 72 pneumoniae co-infections in COVID-19 patients using pneumococcal urinary antigen test 73 (PUATs) ， in addition to those of the secondary infection caused by other pathogens in 74 Southern China. 75 Materials and Methods 76 Setting and patient 77 This study was designed as a prospective, observational cohort study. The Student's T-test when normality was demonstrated; otherwise, Mann-Whitney U was used. All 138 tests were two-tailed, and the statistical significance was set at P < 5%. 139 

Demographic, clinical , laboratory findings and cilinical outcomes 141 The data of baseline demographic characteristics, clinical manifestations and laboratory 142 findings were summarized in Table 1 . During the study period, 146 patients with a confirmed 143 diagnosis of COVID-19 were admitted into the two hospitals. The median age was 50.0 years 144 (IQR 36.0-61.0) and among them 69 patients (48.6%) were male. Hypertension (28, 19.2%) 145 was the most common comorbidity, followed by diabetes (11, 7.5%) and coronary heart disease 146 (8, 5.5%). Cough (76, 52.1%) and fever (41, 28.1%) were the most seen clinical manifestations. 147 The median length of hospital stay was 19 (IQR 13-26) days. 27 patients were transferred to 148 ICU and the median length of ICU stay was 15.5 (IQR 9.5-28.5) days. Based on the American 149 Thoracic Society guidelines for community-acquired pneumonia, 16 (11.0%) patients were 150 considered as severe cases and 130 (89.0%) as non-severe cases. The white blood cell(WBC) 151 count of 39 (26.7%) patients was below the normal range and that of 7 (4.8%) patients was 152 above, Lactate dehydrogenase(LDH) and D-dimer,were abnormal in 65 (44.5%) patients, 153 and 96 (65.8%) patients, respectively. Only one patient showed a higher procalcitonin(PCT) Table 4 . 174 In this study, 99 patients underwent at least one of the following tests including blood culture, 175 urine culture, sputum culture and bronchoalveolar lavage fluid culture 48 hours after admission. [18-20] Among the 3 cases described above, the patient with positive blood 233 culture was dead and the other two with minor or moderate conditions were discharged finally. 234 For secondary infection, we revealed that it occurred in 16.2% COVID-19 patients, similar to 235 the incidence rate reported in previous study.

[8] After dividing our patients into subgroups 236 based on whether they have secondary infections, we observed that patients with senior age 237 and multiple complications were more susceptible to infection due to their weakening immune 238 capability. Our results also disclosed that patients with secondary infections usually had 239 severely illness and required more mechanical ventilations and longer ICU and hospital stay. It should be noted that bacteremia may cause a high mortality in COVID-19 patients (42.9%). 248 All 3 patients with bacteremia died, two of whom were induced by S. maltophilia. We 249 considered this uncommon pathogen is not representative because of its very finite prevalence 250 in the environment and the patients' poor immunity. 251 We inferred that the patterns of co-infection and secondary infection in COVID-19 patients 252 were different from influenza viruses. COVID-19 patients rarely co-infected with S. 

Bacteremia in children: epidemiology, clinical diagnosis 368 and antibiotic treatment

Pneumococcal urinary antigen test: diagnostic yield 370 and impact on antibiotic treatment

Can procalcitonin help identify associated bacterial infection in patients with severe 374 influenza pneumonia? A multicentre study

Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease

Epidemiological and clinical 379 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a 380 descriptive study

Co-infection with SARS-CoV-2 and Human 382

and Influenza A Virus in Patient with Pneumonia

CoV-2 and influenza A virus

SARS-CoV-2 and viral sepsis: 389 observations and hypotheses

Contribution of a Urinary Antigen Assay (Binax NOW) to the Early Diagnosis of 392

 318 We thank Guanyang Zou for his kind advice to the manuscript. We thank all the patients in this 319 study. We thank all the front-line medical staff in the Department of Infectious Diseases of the 320 Third People's Hospital of Shenzhen.

Availability of data and materials 322 The datasets used and/or analysed during the current